John L. Higgins, a director at Bio-Techne Corp, recently reported the purchase of 2,750 shares of the company's common stock. The transaction, dated October 29, 2026, signifies an ongoing commitment to the company as it navigates the competitive landscape of the life sciences sector.

Background

Bio-Techne Corp, incorporated in Minnesota, operates in the biological products sector, specifically focusing on biological products (no diagnostic substances). The company is publicly traded under the ticker symbol TECH. Recent filings indicate that Higgins has been actively managing his stock ownership, with multiple transactions reported throughout the year.

What the Filing Says

According to the recent SEC filing (accession number 0000914190-26-000157), Higgins acquired 2,750 shares on October 29, 2026. Following this transaction, he now owns a total of 80,004 shares of Bio-Techne Corp.

Impact

This update may affect stakeholders, including other directors and shareholders of Bio-Techne, as it reflects a significant level of engagement from Higgins in the company's operations. The life sciences industry is characterized by intense competition, and such transactions can influence investor sentiment and perceptions of company leadership.

What's Next

The filing does not say what happens next.

Ownership Details

In addition to the recent purchase of 2,750 shares, John L. Higgins holds a significant number of stock options. These options include rights to buy 12,500 shares at an exercise price of $31.26, which expire on October 26, 2027, and 7,592 shares at $44.96, expiring on October 25, 2028. Furthermore, Higgins has options for 8,044 shares at $50.41, set to expire on October 24, 2029, and 6,028 shares at $63.92, with an expiration date of October 29, 2030.

Additional stock options include rights to purchase 2,532 shares at $128.81, expiring on October 28, 2031, and 3,460 shares at $73.94, expiring on October 27, 2032. He also has options for 3,937 shares at $61.51, expiring on October 26, 2033, and 3,511 shares at $68.37, with an expiration date of October 24, 2034. Most recently, Higgins has options for 3,777 shares at $60.96, which expire on October 30, 2035.

Reporting and Compliance

The SEC filing was submitted as Form 4, which is a statement of changes in beneficial ownership of securities. This type of filing is crucial for maintaining transparency and compliance with the Securities Exchange Act of 1934. The report was filed on November 2, 2026, reflecting the transaction date of October 29, 2026. The filing also indicates that Higgins is a director of Bio-Techne Corp, confirming his role in the company's governance.

Contact Information

For further inquiries, the mailing address for John L. Higgins is listed as 11119 North Torrey Pines Road, Suite 200, La Jolla, CA 92037. The business address for Bio-Techne Corp is 614 McKinley Place NE, Minneapolis, MN 55413, where they can be reached at 612-379-8854.